HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Dyne Therapeutics (NASDAQ:DYN), maintaining a $36 price target on the stock.
May 03, 2024 | 7:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterates a Buy rating on Dyne Therapeutics, with a maintained price target of $36.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence in Dyne Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100